Research Article| Volume 133, P1-6, March 2020

Evaluation of Femaxeen® for control of urinary incontinence in women: A randomized, double-blind, placebo-controlled study


      • Femaxeen® is a natural product for control of urinary incontinence (UI) in women.
      • This study compared Femaxeen with placebo in women with urge, stress, or mixed urinary incontinence.
      • Femaxeen provided effective control of all three types of urinary incontinence.
      • The safety profile of Femaxeen was similar to that of placebo.
      • Femaxeen is a useful addition to the armamentarium for treating urinary incontinence in women.


      Background and aims

      Urinary incontinence (UI) is common in women, with up to 50 % experiencing involuntary loss of urine at some point. Femaxeen®, a formulation containing purified and specific cytoplasmic extracts of pollen, pumpkin seed extract and vitamin E (referred to hereafter as Femaxeen), is indicated for control of UI in women. This study investigated the efficacy and safety of Femaxeen for the prevention and treatment of UI symptoms in women.


      In this randomized, double-blind, placebo-controlled trial, 81 women with moderate, severe, or very severe urge (43.4 %), stress (31.6 %) or mixed (25.0 %) UI were allocated to receive Femaxeen or placebo once daily for 90 days. Treatment efficacy was assessed using three validated questionnaires.


      Thirty-eight patients per group were analyzed. Femaxeen produced statistically significant improvements from baseline to Day 90 (p < 0.001 for all comparisons) in scores on the International Consultation on Incontinence Questionnaire–Short Form (ICIQ-SF), Measurement of Urinary Handicap (MHU) questionnaire, and Sandvik Incontinence Severity Index. Reduction from baseline in ICIQ-SF and MHU scores at Day 60 and Day 90 was significantly greater with Femaxeen than placebo (p < 0.05 for all comparisons). Femaxeen significantly reduced ICIQ-SF and MHU scores from baseline to Day 60 and Day 90 in all UI types (p < 0.05 for all comparisons except ICIQ-SF scores for stress UI). Femaxeen and placebo were well tolerated. Associated adverse events were few and mild in intensity.


      Femaxeen is effective for treating UI, and has a safety profile comparable to that of placebo.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nambiar A.K.
        • Bosch R.
        • Cruz F.
        • Lemack G.E.
        • Thiruchelvam N.
        • Tubaro A.
        • Bedretdinova D.A.
        • Ambühl D.
        • Farag F.
        • Lombardo R.
        • Schneider M.P.
        • Burkhard F.C.
        EAU guidelines on assessment and nonsurgical management of urinary incontinence.
        Eur. Urol. 2018; 73: 596-609
        • DeMarco E.F.
        Urinary tract disorders in perimenopausal and postmenopausal women.
        in: Lobo R.A. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 2nd ed. Lippincott, Williams & Wilkins, Philadelphia, PA1999: 213-227
        • Minassian V.A.
        • Bazi T.
        • Stewart W.F.
        Clinical epidemiological insights into urinary incontinence.
        Int. Urogynecol. J. 2017; 28: 687-696
        • Minassian V.A.
        • Stewart W.F.
        • Wood G.C.
        Urinary incontinence in women: variation in prevalence estimates and risk factors.
        Obstet. Gynecol. 2008; 111: 324-331
        • Peyrat L.
        • Haillot O.
        • Bruyere F.
        • Boutin J.M.
        • Bertrand P.
        • Lanson Y.
        Prevalence and risk factors of urinary incontinence in young and middle-aged women.
        BJU Int. 2002; 89: 61-66
        • Danforth K.N.
        • Townsend M.K.
        • Lifford K.
        • Curhan G.C.
        • Resnick N.M.
        • Grodstein F.
        Risk factors for urinary incontinence among middle-aged women.
        Am. J. Obstet. Gynecol. 2006; 194: 339-345
        • Botlero R.
        • Davis S.R.
        • Urquhart D.M.
        • Shortreed S.
        • Bell R.J.
        Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire.
        Maturitas. 2009; 62: 134-139
        • Bradway C.
        • Coyne K.S.
        • Irwin D.
        • Kopp Z.
        Lower urinary tract symptoms in women-a common but neglected problem.
        J. Am. Acad. Nurse Pract. 2008; 20: 311-318
        • Milsom I.
        • Abrams P.
        • Cardozo L.
        • Roberts R.G.
        • Thüroff J.
        • Wein A.J.
        How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.
        BJU Int. 2001; 87: 760-766
        • Burkhard F.C.
        • Bosch J.L.H.R.
        • Cruz F.
        • Lemack G.E.
        • Nambiar A.K.
        • Thiruchelvam N.
        • Tubaro A.
        EAU Guidelines on Urinary Incontinence in Adults.
        EAU Guidelines Office, Arnhem, The Netherlands2018 (Available online at: (Accessed June 2019))
        • Demaagd G.A.
        • Davenport T.C.
        Management of urinary incontinence.
        P&T. 2012; 37: 345-361H
        • Lukacz E.S.
        • Santiago-Lastra Y.
        • Albo M.E.
        • Brubaker L.
        Urinary incontinence in women: a review.
        JAMA. 2017; 318: 1592-1604
        • Wilt T.
        • Mac Donald R.
        • Ishani A.
        • Rutks I.
        • Stark G.
        Cernilton for benign prostatic hyperplasia.
        Cochrane Database Syst. Rev. 2002; CD001042
        • Preuss H.G.
        • Bagchi D.
        • Chambliss W.G.
        A critical review of Cernitin™ for symptomatic relief of lower urinary tract symptoms (LUTS) in men.
        Res. Comm. Pharmacol. Toxicol. 2003; 8: 2-10
        • Elist J.
        Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study.
        Urology. 2006; 67: 60-63
        • Sandvik H.
        • Seim A.
        • Vanvik A.
        • Hunskaar S.
        A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests.
        Neurourol. Urodyn. 2000; 19: 137-145
        • Avery K.
        • Donovan J.
        • Peters T.J.
        • Shaw C.
        • Gotoh M.
        • Abrams P.
        ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.
        Neurourol. Urodyn. 2004; 23: 322-330
        • Amarenco G.
        • Kerdraon J.
        • Perrigot M.
        Evaluation scale of the pelvic handicap: measurement of the urinary handicap (MHU).
        in: Pelissier J. Costa P. Lopez S. Mares P. Rééducation vésico-sphinctérienne et ano-rectale. Masson, Paris2007: 498-504
        • Buck A.C.
        • Rees R.W.
        • Ebeling L.
        Treatment of chronic prostatitis and prostatodynia with pollen extract.
        Br. J. Urol. 1989; 64: 496-499
      1. Internal report. Sérélys Pharma, Monaco.

        • Brading A.F.
        Acetylcholine and the overactive bladder.
        Eur. Urol. 2007; 51: 881-883
        • Fowler C.J.
        • Griffiths D.
        • de Groat W.C.
        The neural control of micturition.
        Nat. Rev. Neurosci. 2008; 9: 453-466
        • Zinner N.R.
        Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.
        Expert Opin. Invest. Drugs. 2003; 12: 1559-1566
        • Jost W.H.
        • Marsalek P.
        Duloxetine in the treatment of stress urinary incontinence.
        Ther. Clin. Risk Manag. 2005; 1: 259-264
        • Gossell-Williams M.
        • Davis A.
        • O’Connor N.
        Inhibition of testosterone-induced hyperplasia of the prostate of Sprague-Dawley rats by pumpkin seed oil.
        J. Med. Food. 2006; 9: 284-286
        • Tsai Y.S.
        • Tong Y.C.
        • Cheng J.T.
        • Lee C.H.
        • Yang F.S.
        • Lee H.Y.
        Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats.
        Urol. Int. 2006; 77: 269-274
        • Ho M.H.
        • Bhatia N.N.
        • Bhasin S.
        Anabolic effects of androgens on muscles of female pelvic floor and lower urinary tract.
        Curr. Opin. Obstet. Gynecol. 2004; 16: 405-409
        • Nishimura M.
        • Ohkawara T.
        • Sato H.
        • Takeda H.
        • Nishihira J.
        Pumpkin seed oil extracted from Cucurbita maxima improves urinary disorder in human overactive bladder.
        J. Tradit. Complement. Med. 2014; 4: 72-74
        • Gažová A.
        • Valášková S.
        • Žufková V.
        • Castejon A.M.
        • Kyselovič J.
        Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women.
        J. Tradit. Complement. Med. 2019; 9: 138-142
        • Palacios S.
        • Ramirez M.
        • Lilue M.
        A randomized, double-blind, placebo-controlled clinical trial: evaluating safety and efficacy of a composition of purified and specific cytoplasm extracts of pollen (PSCEP), pumpkin seed extract and vitamin E (Femaxeen®) in women with stress urinary incontinence.
        in: Presented at: 12th European Congress on Menopause and Andropause, 15–17 May 2019, Berlin, Germany2019
        • Riemsma R.
        • Hagen S.
        • Kirschner-Hermanns R.
        • Norton C.
        • Wijk H.
        • Andersson K.E.
        • Chapple C.
        • Spinks J.
        • Wagg A.
        • Hutt E.
        • Misso K.
        • Deshpande S.
        • Kleijnen J.
        • Milsom I.
        Can incontinence be cured? A systematic review of cure rates.
        BMC Med. 2017; 15: 63